Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34652 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Thorsten Oliver Goetze und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Clinical Cancer Research IKF, Frankfurt, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Stomach Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lilly Deutschland.
Abstract (Originalsprache)
Based on results of prior trials (TAGS, REGARD, RAINBOW), the combination of ramucirumab beyond progression with TAS‐102 (trifluridine/tipiracil) seems to be promising in advanced esophagogastric adenocarcinoma (EGA). In this multicenter, non‐randomized, open‐label, investigator‐initiated pilot trial, ramucirumab‐pretreated patients with metastatic EGA received a maximum of 4 cycles of ramucirumab (8 mg/kg i.v. on day 1 and 15, Q2W) plus TAS‐102 (35 mg/m 2 p.o. bid on day 1‐5 and day 8‐12; Q2W). Primary endpoint was tolerability and toxicity, defining a positive trial if the SAE rate according to CTCAE 5.0 will increase
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Clinical Cancer Research IKF, Frankfurt, Germany.
- University Cancer Center Frankfurt, Krankenhaus Nordwest, Frankfurt, Germany.
- University Cancer Center Frankfurt, Goethe University, Frankfurt, Germany.
- Hämatologisch-Onkologische Praxis Eppendorf (HOPE) und Universitäres Cancer Center Hamburg (UCCH), Hamburg, Germany.
- München Klinikum rechts der Isar der TU München III. Medizinische Klinik und Poliklinik, Munich, Germany.
ORCID-Profile: Maria Loose
Förderung
- Lilly Deutschland
Zitieren
APA
Goetze, T. O., Stein, A., Lorenzen, S., Habibzada, T., Goekkurt, E., Herhaus, P., Loose, M., Sookthai, D., Brulin, T., Ihrig, K., Pauligk, C., & Al-Batran, S. E. (2023). Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.34652
Vancouver
Goetze TO, Stein A, Lorenzen S, Habibzada T, Goekkurt E, Herhaus P, et al. Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy. International Journal of Cancer. 2023. doi:10.1002/ijc.34652
BibTeX
@article{Goetze2023,
author = {Goetze, Thorsten Oliver and Stein, Alexander and Lorenzen, Sylvie and Habibzada, Timorshah and Goekkurt, Eray and Herhaus, Peter and Loose, Maria and Sookthai, Disorn and Brulin, Tanita and Ihrig, Kristina and Pauligk, Claudia and Al-Batran, Salah-Eddin},
title = {Ramucirumab beyond progression plus TAS ‐102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab‐based therapy},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34652}
}
EUVIMED